ArticleJournal of Cancer2019
Down-regulation of miR-338-3p and Up-regulation of MACC1 Indicated Poor Prognosis of Epithelial Ovarian Cancer Patients.
Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Potential Prognostic and Metastatic Implications of MACC1 and MMP8 in Colorectal Cancer.Current issues in molecular biology · 2026Article
- The Role of microRNA in the Prognosis and Diagnosis of Ovarian Cancer.International journal of molecular sciences · 2025Review
- MicroRNA-597-3p targets MACC1 to suppress proliferation and invasion of human ovarian cancer cells.PeerJ · 2025Article
- MicroRNAs, long non-coding RNAs, and circular RNAs and gynecological cancers: focus on metastasis.Frontiers in oncology · 2023Review
- Abnormal expressions of PURPL, miR-363-3p and ADAM10 predicted poor prognosis for patients with ovarian serous cystadenocarcinoma.Journal of Cancer · 2023Article
- Exosomal miR-338-3p suppresses non-small-cell lung cancer cells metastasis by inhibiting CHL1 through the MAPK signaling pathway.Cell death & disease · 2021Article
- Upregulation of MicroRNA-34a Sensitizes Ovarian Cancer Cells to Resveratrol by Targeting Bcl-2.Yonsei medical journal · 2021Article
- Mir-139-5p inhibits glioma cell proliferation and progression by targeting GABRA1.Journal of translational medicine · 2021Article
- Molecular interactions of miR-338 during tumor progression and metastasis.Cellular & molecular biology letters · 2021Review
- Long non-coding RNA SNHG20 promotes ovarian cancer development by targeting microRNA-338-3p to regulate MCL1 expression.Oncology letters · 2021Article
- CircHIPK2 Contributes to DDP Resistance and Malignant Behaviors of DDP-Resistant Ovarian Cancer Cells Both in vitro and in vivo Through circHIPK2/miR-338-3p/CHTOP ceRNA Pathway.OncoTargets and therapy · 2021Article
- miR-338-3p inhibits cell growth, invasion, and EMT process in neuroblastoma through targeting MMP-2.Open life sciences · 2021Article
- Disregulations of PURPL and MiR-338-3p Could Serve As Prognosis Biomarkers for Epithelial Ovarian Cancer.Journal of Cancer · 2021Article
- Paeonol suppresses the effect of ox-LDL on mice vascular endothelial cells by regulating miR-338-3p/TET2 axis in atherosclerosis.Molecular and cellular biochemistry · 2020Article
- Long non‑coding RNA BANCR mediates esophageal squamous cell carcinoma progression by regulating the IGF1R/Raf/MEK/ERK pathway via miR‑338‑3p.International journal of molecular medicine · 2020Article
- The Role of microRNAs in Epithelial Ovarian Cancer Metastasis.International journal of molecular sciences · 2020Review
- Circular RNA HIPK3 Promotes EMT of Cervical Cancer Through Sponging miR-338-3p to Up-Regulate HIF-1α.Cancer management and research · 2020Article
- MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.Journal of experimental & clinical cancer research : CR · 2019Article
- Circ_0000003 promotes the proliferation and metastasis of non-small cell lung cancer cells via miR-338-3p/insulin receptor substrate 2.Cell cycle (Georgetown, Tex.) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.